TY - JOUR
T1 - Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea
T2 - A randomized, double-blind clinical trial
AU - DuPont, Herbert L.
AU - Jiang, Zhi Dong
AU - Ericsson, Charles D.
AU - Adachi, Javier A.
AU - Mathewson, John J.
AU - DuPont, Margaret W.
AU - Palazzini, Ernesto
AU - Riopel, Lise M.
AU - Ashley, David
AU - Sandoval, Francisco Martinez
PY - 2001/12/1
Y1 - 2001/12/1
N2 - Rifaximin is a poorly absorbed rifamycin derivative under investigation for treatment of infectious diarrhea. Adult students from the United States in Mexico and international tourists in Jamaica were randomized to receive either rifaximin (400 mg twice per day) or ciprofloxacin (500 mg twice per day) for 3 days, following a double-blinded model, from June 1997 to September 1998. A total of 187 subjects with diarrhea were studied. Time from initiation of therapy to passage of last unformed stool was comparable for those receiving rifaximin or ciprofloxacin (median, 25.7 hours versus 25.0 hours, respectively). There was no significant difference in the proportion of subjects in the 2 groups with respect to clinical improvement during the first 24 hours (P = .199), failure to respond to treatment (P = .411), or microbiological cure (P = .222). The incidence of adverse events was low and similar in each group. Rifaximin is a safe and effective alternative to ciprofloxacin in the treatment of traveler's diarrhea.
AB - Rifaximin is a poorly absorbed rifamycin derivative under investigation for treatment of infectious diarrhea. Adult students from the United States in Mexico and international tourists in Jamaica were randomized to receive either rifaximin (400 mg twice per day) or ciprofloxacin (500 mg twice per day) for 3 days, following a double-blinded model, from June 1997 to September 1998. A total of 187 subjects with diarrhea were studied. Time from initiation of therapy to passage of last unformed stool was comparable for those receiving rifaximin or ciprofloxacin (median, 25.7 hours versus 25.0 hours, respectively). There was no significant difference in the proportion of subjects in the 2 groups with respect to clinical improvement during the first 24 hours (P = .199), failure to respond to treatment (P = .411), or microbiological cure (P = .222). The incidence of adverse events was low and similar in each group. Rifaximin is a safe and effective alternative to ciprofloxacin in the treatment of traveler's diarrhea.
UR - http://www.scopus.com/inward/record.url?scp=0035576899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035576899&partnerID=8YFLogxK
U2 - 10.1086/323814
DO - 10.1086/323814
M3 - Article
C2 - 11692292
AN - SCOPUS:0035576899
SN - 1058-4838
VL - 33
SP - 1807
EP - 1815
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 11
ER -